[CAS NO. 68-41-7] D-Cycloserine

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [68-41-7]

Catalog

HY-B0030

Brand

MCE

CAS

68-41-7

DESCRIPTION [68-41-7]

Overview

MDL	MFCD00005353
Molecular Weight	102.09
Molecular Formula	C3H6N2O2
SMILES	O=C1[C@H](N)CON1

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

Summary

D-Cycloserine is an antibiotic which targets sequential bacterial cell wall peptidoglycan biosynthesis enzymes. D-Cycloserine is a partial NMDA agonist that can improve cognitive functions. D-Cycloserine can be used for multidrug-resistant tuberculosis research ^[1] ^[2] .

IC50 & Target

NMDA Receptor

In Vivo

D-Cycloserine selectively potentiates the duration of motor cortical excitability enhancements induced by anodal transcranial direct current (tDCS). D-Cycloserine alone does not modulate excitability. ^[1] .
Chronic D-Cycloserine (40 mg/kg; 5 days/week; for 2 weeks) significantly reduces nicotine self-administration selectively in rats with low baseline nicotine use, but is ineffective with the rats with higher levels of baseline nicotine self-administration ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00963924	Massachusetts General Hospital\|National Institute of Mental Health (NIMH)	Schizophrenia	August 2009	Not Applicable
NCT01404208	Massachusetts General Hospital\|National Institute of Mental Health (NIMH)\|University of South Florida	Obsessive-Compulsive Disorder	July 2011	Not Applicable
NCT01399866	Massachusetts General Hospital	Smoking Cessation	May 2011	Phase 3
NCT05395494	University of Calgary	Fibromyalgia	August 29, 2022	Phase 2
NCT00198120	Indiana University\|National Institute of Mental Health (NIMH)\|National Alliance for Research on Schizophrenia and Depression\|Indiana University School of Medicine	Autistic Disorder	February 2004	Phase 3
NCT00926900	Central Institute of Mental Health, Mannheim\|German Research Foundation	Alcohol Drinking	March 2009	Phase 2\|Phase 3
NCT00452231	Université de Montréal\|Centre de Recherche de l´Institut Universitaire en santé Mentale de Montréal	Post-Traumatic Stress Disorder	February 2007	Phase 2\|Phase 3
NCT00855153	United States Army Institute of Surgical Research	Psychological Trauma	May 2009	Not Applicable
NCT00000371	Massachusetts General Hospital	Schizophrenia	August 1996	Phase 3
NCT03535688	Northwestern University\|United States Department of Defense	Low Back Pain\|Pain	March 30, 2018	Phase 2
NCT00632632	Weill Medical College of Cornell University	Posttraumatic Stress Disorder	January 2005	Not Applicable
NCT00125528	Thomas J. Schnitzer\|Northwestern University	Low Back Pain\|Pain	July 2012	Phase 2
NCT00198107	Indiana University\|National Institute of Mental Health (NIMH)	Autistic Disorder	September 2005	Phase 3
NCT01102803	Southern Methodist University	Phobic Disorders	April 2010	Phase 3
NCT01037101	CAMC Health System\|West Virginia University\|University of Charleston	Height Phobia	July 2009	Not Applicable
NCT00128401	National Institute of Mental Health (NIMH)\|National Institutes of Health Clinical Center (CC)	Phobic Disorders\|Anxiety\|Social Phobia	August 2005	Phase 2
NCT00356278	Emory University\|National Institute of Mental Health (NIMH)	Stress Disorder, Post Traumatic	September 2006	Phase 2\|Phase 3
NCT02082912	Emory University	Stroke	June 2010	Phase 2
NCT00742079	Massachusetts General Hospital\|National Institute of Mental Health (NIMH)	Schizophrenia	September 2006	Phase 4
NCT00720759	US Department of Veterans Affairs\|VA Office of Research and Development	Stroke	July 2009	Phase 2
NCT01157429	Tulane University School of Medicine\|National Alliance for Research on Schizophrenia and Depression\|Tulane University	Posttraumatic Stress Disorder\|PTSD	June 2010	Phase 2
NCT02769936	University of California, Los Angeles	Schizophrenia	November 2013	Phase 1
NCT01172873	New York State Psychiatric Institute\|Emory University	Obsessive Compulsive Disorder	September 2008	Not Applicable
NCT03062150	Charite University, Berlin, Germany\|NeuroCure Clinical Research Center, Charite, Berlin	Major Depression	September 27, 2016	Not Applicable
NCT00759473	Medical University of South Carolina\|National Institute on Drug Abuse (NIDA)	Cocaine Use Disorders	September 2008	Phase 2
NCT02312635	University of California, Los Angeles	Traumatic Brain Injury	December 2012	Early Phase 1
NCT01490697	Roger K. Pitman, MD\|Massachusetts General Hospital	Post-traumatic Stress Disorder	March 2009	Phase 4
NCT01680107	University of Oxford\|Medical Research Council	Panic Disorder	October 2012	Phase 3
NCT00790868	Boston University Charles River Campus\|National Institute on Drug Abuse (NIDA)\|National Institute of Mental Health (NIMH)	Panic Disorder	April 2008	Phase 2
NCT02066792	University of Texas at Austin\|Rush University Medical Center\|Boston University\|Southern Methodist University	Social Anxiety Disorder	April 2014	Early Phase 1
NCT01923896	Emory University	Feeding Disorders\|Specific Phobia	March 2013	Phase 1\|Phase 2
NCT00674570	VA Office of Research and Development	Stress Disorders, Posttraumatic	January 13, 2009	Phase 4
NCT00257361	University of Florida\|Obsessive Compulsive Foundation	Obsessive Compulsive Disorder	July 2005	Phase 2
NCT00591825	University of Kansas Medical Center\|American Psychological Foundation\|American Psychological Association	Phobias	March 2006	Phase 2
NCT00633984	Massachusetts General Hospital\|Boston University\|Southern Methodist University\|National Institutes of Health (NIH)\|National Institute of Mental Health (NIMH)	Social Anxiety Disorder	March 2007	Phase 4
NCT00827281	Boston University Charles River Campus	Smokers	August 2008	Phase 2
NCT04762836	Leiden University Medical Center\|Leiden University	Chronic Pain\|Pain Syndrome	February 28, 2021	Not Applicable
NCT01649895	Christian Rück\|The Swedish Research Council\|Königska\|Region Stockholm\|Karolinska Institutet	Obsessive-compulsive Disorder	August 2012	Phase 4
NCT00000372	Massachusetts General Hospital	Schizophrenia	March 1998	Phase 3
NCT02983734	Boston University Charles River Campus	Gulf War Illness	October 2015	Phase 2
NCT01687140	University of California, Los Angeles	Obsessive-Compulsive Disorder	July 2012	Phase 2
NCT02385266	Northwestern University\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Institutes of Health (NIH)	Chronic Prostatitis With Chronic Pelvic Pain Syndrome	September 2013	Phase 4
NCT04035603	Boston University Charles River Campus\|National Institute on Drug Abuse (NIDA)	Smoking Cessation	October 1, 2020	Phase 2
NCT01157416	Tulane University School of Medicine\|National Institute of Mental Health (NIMH)\|Tulane University	Posttraumatic Stress Disorders\|PTSD	June 2010	Phase 2
NCT00131339	Hartford Hospital	Panic Disorder	November 2004	Not Applicable
NCT02099825	Washington University School of Medicine	Anxiety Disorders	January 13, 2014	Phase 1
NCT01928823	Charite University, Berlin, Germany\|German Federal Ministry of Education and Research	Agoraphobia	November 2011	Phase 2
NCT01907594	New York State Psychiatric Institute	Cigarette Smoking	August 2013	Phase 2
NCT03961464	University of Oxford	Cycloserine\|Healthy Volunteer	August 10, 2018	Not Applicable
NCT00842309	Massachusetts General Hospital	Body Dysmorphic Disorder	November 2008	Early Phase 1
NCT00864123	University of South Florida	Obsessive-compulsive Disorder	January 2008	Phase 2
NCT04357951	Johns Hopkins University	Tourette Syndrome	December 15, 2022	Early Phase 1
NCT00755820	New York State Psychiatric Institute\|The Hilda & Preston Davis Foundation\|National Alliance for Research on Schizophrenia and Depression	Anorexia Nervosa	January 2008
NCT01135953	The University of New South Wales	Healthy Volunteers\|Brain Excitation	January 2010	Not Applicable
NCT01450306	Hartford Hospital	Specific Phobia	July 2010	Not Applicable
NCT03216356	Boston University Charles River Campus\|James S McDonnell Foundation	PTSD	September 2016	Phase 2\|Phase 3
NCT00635102	Yale University	Alcohol Dependence	October 1997	Not Applicable
NCT00964041	Massachusetts General Hospital\|National Institute of Mental Health (NIMH)	Schizophrenia	July 2009	Phase 4
NCT01411774	University of South Florida\|Massachusetts General Hospital	Obsessive-compulsive Disorder	June 2011	Phase 3
NCT00408031	Herzog Hospital\|National Alliance for Research on Schizophrenia and Depression	Major Depressive Disorder	January 2007	Phase 2
NCT02656342	Haukeland University Hospital\|The Research Council of Norway\|Helse Vest	Obsessive-Compulsive Disorder	November 2015	Phase 4
NCT01343862	Hadassah Medical Organization	Traumatic Brain Injury	August 2011	Phase 2
NCT01833897	New York State Psychiatric Institute	Bipolar Disorder	March 2013	Phase 4
NCT00301080	Northwestern University	Neurotoxicity\|Pain\|Breast Cancer	February 2006	Phase 3
NCT00869765	The University of New South Wales	Major Depressive Disorder\|Bipolar Disorder	April 2009	Phase 2
NCT02635893	Shirley Ryan AbilityLab\|The Craig H. Neilsen Foundation	Spinal Cord Injury	June 21, 2019	Phase 4
NCT02772211	Sheba Medical Center\|Teva Pharmaceuticals USA\|Tel Aviv University	Treatment Resistant Depression	June 2016	Phase 4
NCT02687165	New York State Psychiatric Institute	Post Treatment Lyme Syndrome (PTLS)\|Chronic Pain	January 16, 2016	Not Applicable
NCT02582515	University of California, Los Angeles	Tourette Disorder\|Chronic Tic Disorder	October 2015	Not Applicable
NCT03937596	University of Calgary	Major Depressive Disorder	December 1, 2019	Phase 2
NCT00371176	US Department of Veterans Affairs\|VA Office of Research and Development	Combat Disorders\|Stress Disorders, Post-Traumatic	October 2006	Not Applicable
NCT01981759	NYU Langone Health\|National Institute of Mental Health (NIMH)	Schizophrenia\|Schizoaffective Disorder\|Delusional Disorder	February 2014	Phase 4
NCT00515879	Boston University Charles River Campus\|National Institute of Mental Health (NIMH)	Social Anxiety Disorder	December 2007	Phase 3
NCT02304432	Mclean Hospital\|University of Minnesota	Schizophrenia\|Bipolar Disorder	September 27, 2015	Early Phase 1
NCT05177601	University of Calgary	Obsessive-Compulsive Disorder	November 26, 2021	Phase 2
NCT05591677	The Alfred\|Blue Bell Health, Australia\|Gold Coast Hospital and Health Service	Major Depressive Disorder	December 2022	Phase 2
NCT01512316	Universitaire Ziekenhuizen KU Leuven	Healthy Individuals		Not Applicable
NCT00126282	Massachusetts General Hospital	Obsessive-Compulsive Disorder	December 2003	Not Applicable
NCT00455702	Massachusetts General Hospital	Schizophrenia	July 2004	Phase 4
NCT01526538	Johns Hopkins University\|National Institute on Drug Abuse (NIDA)	COCAINE-RELATED DISORDERS	September 2011	Phase 2
NCT01934972	University of Arizona	Bipolar Disorder	March 2013	Phase 3
NCT01086475	Indiana University\|United States Department of Defense	Autistic Disorder\|Asperger´s Disorder\|Pervasive Developmental Disorder NOS	March 2010	Phase 3
NCT00222235	University of Maryland, Baltimore\|National Institute of Mental Health (NIMH)\|The Zucker Hillside Hospital\|Nathan Kline Institute for Psychiatric Research\|University of California, Los Angeles\|Sarah Herzog Hospital\|University of Maryland, College Park	Schizophrenia\|Schizoaffective Disorder	January 2000	Phase 2\|Phase 3
NCT00780442	Medical University of South Carolina	Cocaine Use Disorders	September 2006	Phase 2
NCT01944423	University of Texas at Austin	Nicotine Addiction\|Panic Attack	October 2013	Early Phase 1
NCT03780829	VA Office of Research and Development	SCI	February 25, 2020	Early Phase 1
NCT01361633	Hartford Hospital	Treatment\|Placebo	January 2008	Phase 2
NCT00430573	Boston University Charles River Campus\|National Institute on Drug Abuse (NIDA)\|Massachusetts General Hospital	Substance-Related Disorders	February 2007	Phase 2
NCT01985750	University of Oxford\|National Health Service, United Kingdom	Chronic Obstructive Pulmonary Disease	November 2013	Early Phase 1

Appearance

Solid

Source

Streptomyces

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

H ₂ O : 25 mg/mL ( 244.88 mM ; Need ultrasonic)

DMSO : 1 mg/mL ( 9.80 mM ; Need warming)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	9.7953 mL	48.9764 mL	97.9528 mL
5 mM	1.9591 mL	9.7953 mL	19.5906 mL
10 mM	0.9795 mL	4.8976 mL	9.7953 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 11.11 mg/mL (108.83 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

Synonyms

3-Isoxazolidinone, 4-amino-, (4R)-

3-Isoxazolidinone, 4-amino-, (+)-

3-Isoxazolidinone, 4-amino-, (R)-

(4R)-4-Amino-3-isoxazolidinone

D-4-Amino-3-isoxazolidone

Cyclo-D-serine

Oxamycin

d-4-Amino-3-isoxazolidinone

D-4-Amino-3-isoxazolidinone

(+)-Cycloserine

α-Cycloserine

Cycloserine

Orientomycin

Cyclorin

Farmiserina

Tisomycin

Miroseryn

Wasserina

Novoserin

D-Cycloserine

(R)-(+)-Cycloserine

(R)-Cycloserine

D-CS

Seromycin

(R)-4-Amino-3-isoxazolidinone

Closerin

Micoserina

PA 94

Closina

NSC 154851

NSC 76029

(R)-4-Aminoisoxazolidin-3-one

(4R)-4-Amino-1,2-oxazolidin-3-one